Skip to main content
SpringerLink
Log in

ASH 2016 − Schlaglichter von der Jahrestagung der amerikanischen Hämatologen

San Diego, 02.−06.12.2016

ASH 2016 − Highlights from the annual meeting of American hematologists

San Diego, 2–6 December 2016

  • Onkologiekongresse
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Neelapu S et al (2016) LBA-6 Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B‑Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1. ASH 2016. (abstr. LBA-6)

  2. Crump M et al (2016) Outcomes in refractory aggressive diffuse large b‑cell lymphoma (DLBCL): results from the international SCHOLAR-1 study. J Clin Oncol 34(suppl):abstr. 7516

    Google Scholar 

  3. Locke FL et al (2016) A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B‑Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL):  Interim Results From ZUMA-1. ASH 2016. (abstr. 998)

    Google Scholar 

  4. Shah NN et al (2016) Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 Chimeric Antigen Receptor (CAR) in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL). ASH 2016. (abstr. 650)

    Google Scholar 

  5. Marcus RE et al (2016) Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. ASH 2016. (abstr. 6)

    Google Scholar 

  6. Schrappe M et al (2016) Reduced Intensity Delayed Intensification in Standard-Risk Patients Defined By Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Results of an International Randomized Trial in 1164 Patients (Trial AIEOP-BFM ALL 2000). ASH 2016. (abstr. 4)

    Google Scholar 

  7. Stadtmauer EA et al (2016) LBA-1 Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). ASH 2016. (abstr. LBA-1)

  8. Pan D, Doctor A et al (2016) Erythromer (EM), a Nanoscale Bio-Synthetic Artificial Red Cell: Proof of Concept and In Vivo Efficacy Results. ASH 2016. (abstr. 1027)

    Google Scholar 

  9. Stavrou EX et al (2016) A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation. ASH 2016. (abstr. 3754)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sellscheid 100, 42929, Wermelskirchen, Deutschland

    Annette Junker

Authors
  1. Annette Junker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annette Junker.

Ethics declarations

Interessenkonflikt

A. Junker gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von der Autorin durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Junker, A. ASH 2016 − Schlaglichter von der Jahrestagung der amerikanischen Hämatologen. Onkologe 23, 228–231 (2017). https://doi.org/10.1007/s00761-017-0192-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-017-0192-z

Search

Navigation